23andMe Reports Q1 Revenue Drop, Narrows Losses

Financial Performance Highlights

23andMe Holding Co. (ME), an influential player in personal genomics, recently revealed its fiscal Q1 2025 financial results. The company experienced a 34% revenue drop, recording $40 million, primarily due to ending a collaboration with GSK. However, 23andMe managed to reduce its net loss to $69 million from last year’s $105 million, indicating an improvement in financial health.